World's Largest SAB Trial Launched to Fight Deadly Infection
The world's largest clinical trial on Staphylococcus aureus bacteremia (SAB), the international platform trial 'Staphylococcus aureus Network Adaptive Platform' (SNAP), is underway. Led by Magdeburg University Medical Center, the study aims to reduce the morbidity and mortality of this potentially life-threatening news today. It is enrolling 500 participants in Germany across 18 study centers, with the first patient enrolled by Magdeburg University Medical Center.
The SNAP study is a multifaceted, adaptive platform trial investigating various news in parallel or sequentially across several study arms. Before this study, fewer than 3,000 patients worldwide had been investigated in intervention studies for the treatment of SAB. The study is funded by the Ministry of Science, Energy, Climate Protection and the Environment (MWU) of Saxony-Anhalt and the Federal Ministry of Education and Research (BMBF) within the framework of the Network University Medicine (NUM).
The study has already yielded relevant news regarding the use of penicillin antibiotics and allows for the continuous development of new study arms to address relevant questions. Individuals who cannot or do not wish to participate in the platform study can donate their data to a prospective registry, with over 4,700 patients already participating worldwide. The Institute of Medical Microbiology and Hospital Hygiene at Magdeburg University will oversee the establishment of the European strain collection and investigate new approaches for combating the bacteria. The study is investigating new medicinal treatment strategies for SAB, which is the leading cause of infection-related deaths worldwide.
The SNAP study, coordinated by the Institute for Medical Microbiology and Hospital Hygiene at Otto-von-Guericke-University Magdeburg, is a significant step towards combating Staphylococcus aureus bacteremia. With 18 centers recruiting and following 500 participants, the study is expected to provide valuable insights into new treatment strategies, ultimately reducing the impact of this deadly news today.
